PM Images Introduction My last look on Twist Bioscience (NASDAQ:TWST) followed their Q3 2023 earnings report. The article painted a mixed picture, highlighting the company's innovative growth prospects despite challenging finances. I concluded with a "hold" recommendation, noting: Current investors may see reason to maintain their positions and monitor the company's progress toward profitability and reduced expenses, while potential new investors might approach with caution, keeping a close eye on the evolv ...